Cargando…

The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel

BACKGROUND: Paclitaxel plays a central role in chemotherapy for breast cancer. Peripheral neuropathy, a well-known toxicity with paclitaxel, may be of interest in predicting the efficacy of paclitaxel therapy for patients with metastatic breast cancer. We performed a retrospective analysis assessing...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukada, Ippei, Ito, Yoshinori, Kobayashi, Kokoro, Shibayama, Tomoko, Takahashi, Shunji, Horii, Rie, Akiyama, Futoshi, Iwase, Takuji, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595337/
https://www.ncbi.nlm.nih.gov/pubmed/28898275
http://dx.doi.org/10.1371/journal.pone.0184322
_version_ 1783263355206631424
author Fukada, Ippei
Ito, Yoshinori
Kobayashi, Kokoro
Shibayama, Tomoko
Takahashi, Shunji
Horii, Rie
Akiyama, Futoshi
Iwase, Takuji
Ohno, Shinji
author_facet Fukada, Ippei
Ito, Yoshinori
Kobayashi, Kokoro
Shibayama, Tomoko
Takahashi, Shunji
Horii, Rie
Akiyama, Futoshi
Iwase, Takuji
Ohno, Shinji
author_sort Fukada, Ippei
collection PubMed
description BACKGROUND: Paclitaxel plays a central role in chemotherapy for breast cancer. Peripheral neuropathy, a well-known toxicity with paclitaxel, may be of interest in predicting the efficacy of paclitaxel therapy for patients with metastatic breast cancer. We performed a retrospective analysis assessing whether the early occurrence of peripheral neuropathy (EPN) was a predictive marker for better efficacy in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel. PATIENTS AND METHODS: Between January 2000 and August 2008, we examined the records of 168 patients with metastatic breast cancer treated with paclitaxel in our hospital. EPN was defined as a symptom of Grade 2 or more during first three months of treatment. The overall response rate (ORR) and time to treatment failure (TTF) in each group were analyzed retrospectively. RESULTS: Of 168 patients with metastatic breast cancer who were treated with paclitaxel, EPN was documented in 101 patients (60.1%). The clinical benefit rate (CR, PR, and SD ≥ 6 months) was 72.3% in the EPN group and 49.3% in the non-EPN group (p = 0.002). The TTF of the EPN group (median 11.2 months, 95% CI: 9.5–12.9) was significantly longer than that of the non-EPN group (5.7 months, 95% CI: 4.6–6.8) (p<0.001). Multivariate analysis demonstrated that EPN (p<0.001), dose intensity of less than 70% (p<0.001), and the history of microtubule agents (p = 0.001) were the significant favorable prognostic factors for TTF. CONCLUSION: The early onset of peripheral neuropathy might be a robust predictor for TTF in patients with metastatic breast cancer treated with paclitaxel.
format Online
Article
Text
id pubmed-5595337
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55953372017-09-15 The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel Fukada, Ippei Ito, Yoshinori Kobayashi, Kokoro Shibayama, Tomoko Takahashi, Shunji Horii, Rie Akiyama, Futoshi Iwase, Takuji Ohno, Shinji PLoS One Research Article BACKGROUND: Paclitaxel plays a central role in chemotherapy for breast cancer. Peripheral neuropathy, a well-known toxicity with paclitaxel, may be of interest in predicting the efficacy of paclitaxel therapy for patients with metastatic breast cancer. We performed a retrospective analysis assessing whether the early occurrence of peripheral neuropathy (EPN) was a predictive marker for better efficacy in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel. PATIENTS AND METHODS: Between January 2000 and August 2008, we examined the records of 168 patients with metastatic breast cancer treated with paclitaxel in our hospital. EPN was defined as a symptom of Grade 2 or more during first three months of treatment. The overall response rate (ORR) and time to treatment failure (TTF) in each group were analyzed retrospectively. RESULTS: Of 168 patients with metastatic breast cancer who were treated with paclitaxel, EPN was documented in 101 patients (60.1%). The clinical benefit rate (CR, PR, and SD ≥ 6 months) was 72.3% in the EPN group and 49.3% in the non-EPN group (p = 0.002). The TTF of the EPN group (median 11.2 months, 95% CI: 9.5–12.9) was significantly longer than that of the non-EPN group (5.7 months, 95% CI: 4.6–6.8) (p<0.001). Multivariate analysis demonstrated that EPN (p<0.001), dose intensity of less than 70% (p<0.001), and the history of microtubule agents (p = 0.001) were the significant favorable prognostic factors for TTF. CONCLUSION: The early onset of peripheral neuropathy might be a robust predictor for TTF in patients with metastatic breast cancer treated with paclitaxel. Public Library of Science 2017-09-12 /pmc/articles/PMC5595337/ /pubmed/28898275 http://dx.doi.org/10.1371/journal.pone.0184322 Text en © 2017 Fukada et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fukada, Ippei
Ito, Yoshinori
Kobayashi, Kokoro
Shibayama, Tomoko
Takahashi, Shunji
Horii, Rie
Akiyama, Futoshi
Iwase, Takuji
Ohno, Shinji
The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
title The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
title_full The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
title_fullStr The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
title_full_unstemmed The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
title_short The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
title_sort early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595337/
https://www.ncbi.nlm.nih.gov/pubmed/28898275
http://dx.doi.org/10.1371/journal.pone.0184322
work_keys_str_mv AT fukadaippei theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT itoyoshinori theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT kobayashikokoro theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT shibayamatomoko theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT takahashishunji theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT horiirie theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT akiyamafutoshi theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT iwasetakuji theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT ohnoshinji theearlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT fukadaippei earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT itoyoshinori earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT kobayashikokoro earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT shibayamatomoko earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT takahashishunji earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT horiirie earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT akiyamafutoshi earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT iwasetakuji earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel
AT ohnoshinji earlyonsetofperipheralneuropathymightbearobustpredictorfortimetotreatmentfailureinpatientswithmetastaticbreastcancerreceivingchemotherapycontainingpaclitaxel